# OncoC4

Source: https://onco.cc/companies/oncoc4/  
OnCo record `oncoc4` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OncoC4 is a United States-based biotechnology company running 5 late-stage cancer trials of ONC-392, AI-081 and ONC-392 low in non-small-cell lung cancer, melanoma and head and neck squamous cell carcinoma.

## Summary

OncoC4, based in Rockville, MD, the United States, is a biotechnology company. A clinical-stage biotechnology company developing immunotherapies (monoclonal and bispecific antibodies, antibody-drug conjugates) for cancer and Alzheimer's disease, targeting CTLA-4, PD-1/VEGF, Siglec and CD24 pathways; grew out of the founders' prior work at OncoImmune following its acquisition by Merck. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing ONC-392, AI-081, ONC-392 low, ONC-392 high and Gotistobart in non-small-cell lung cancer, melanoma, head and neck squamous cell carcinoma, renal cell carcinoma and colorectal cancer. The largest, NCT04140526 (Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumours and NSCLC), plans to enrol 733 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: OncoC4, Inc.
- Tags: ctgov-sponsor
- HQ: Rockville, MD
- Type: biotech
- Website: https://www.oncoc4.com

## Sources

- Official website: https://www.oncoc4.com
- ClinicalTrials.gov: trials led by OncoC4: https://clinicaltrials.gov/search?lead=OncoC4%2C%20Inc.
- Pipeline page: https://www.oncoc4.com/en/pipeline/pipeline/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [AI-081](https://onco.cc/drugs/ai-081/), [Gotistobart](https://onco.cc/drugs/gotistobart/)
- trials: [ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer](https://onco.cc/trials/nct05446298/), [ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC](https://onco.cc/trials/nct05682443/), [ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors](https://onco.cc/trials/nct05671510/), [Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors](https://onco.cc/trials/nct06635785/), [Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC](https://onco.cc/trials/nct04140526/)

---
JSON: https://onco.cc/api/v1/entities/oncoc4.json